News - Mergers & Acquisitions, Licensing

Filter

Popular Filters

1 to 25 of 61 results

Merck KGaA may look to biosimilars and acquisitions for growth

Merck KGaA may look to biosimilars and acquisitions for growth

12-05-2014

German pharma and chemical major Merck KGaA has said it is planning to invest in innovations to ensure…

BiosimilarsLicensingMerck KGaAMergers & AcquisitionsPharmaceutical

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

Bayer shells out $14.2 billion for Merck & Co OTC business; firms to collaborate on sGC modulators

06-05-2014

Confirming strong rumors over the past week or so, German pharma major Bayer confirmed it has agreed…

AdempasBayerLicensingMerck & CoMergers & AcquisitionsPharmaceuticalResearchRespiratory and Pulmonaryvericiguat

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

Roche in deal with Oryzon to develop epigenetics-based medicines; Buys IQuum

07-04-2014

Swiss drug major Roche has entered to a worldwide collaboration with Spanish functional genomics firm…

BiotechnologyIQuumLicensingMergers & AcquisitionsOncologyORY-1001Oryzon GenomicsRoche

Second collaboration between FORMA Therapeutics and Celgene

02-04-2014

Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

17-03-2014

Shares of Five Prime Therapeutics leapt 15% to $21.48 in early trading, after the company said it has…

Bristol-Myers SquibbFive Prime TherapeuticsLicensingMergers & AcquisitionsOncologyPharmaceutical

Abide Therapeutics in deal with Celgene on immune disorders research

03-03-2014

Privately-held Abide Therapeutics has entered into a strategic collaboration with US biotech firm Celgene…

AB101131Abide TherapeuticsBiotechnologyCelgeneImmunologicalsInflammatory diseasesLicensingMergers & Acquisitions

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

Novo Nordisk ups stake in Innate Pharma along with sale of anti-NKG2A

07-02-2014

Danish insulin giant Novo Nordisk has sold full development and commercialization rights to the anti-NKG2A…

anti-NKG2AInnate PharmaLicensingMergers & AcquisitionsNovo NordiskOncologyPharmaceutical

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets

Astellas partners with ClearPath to build vaccine portfolio; sells fermentation assets

06-01-2014

Japanese drug major Astellas Pharma has entered into a strategic partnership with ClearPath Development…

Antibiotics and Infectious diseasesAstellas PharmaClearPath DevelopmentLicensingMergers & AcquisitionsMymetics CorpOtsukaPharmaceuticalRSV CorpTaiho Pharmaceutical

Retrophin to acquire Kyalin Biosciences; in-licenses Syntocinon

13-12-2013

In a second takeover bid within a matter of months, USA-based Retrophin announced that it will acquire…

Kyalin BiosciencesLicensingMergers & AcquisitionsNeurologicalNorth AmericaNovartisPharmaceuticalRetrophinSyntocinonWomen's Health

Advaxis rockets on out-licensing ADXS-HPV in Asia

09-12-2013

Shares of US cancer drug developer Advaxis leapt 22% to $4.38 in pre-market trading as the company revealed…

AdvaxisADXS-HPVBiotechnologyGlobal BioPharmaLicensingMergers & AcquisitionsOncologyTaiwan Biotech

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Collaboration agreement between French firms Vect-Horus and AAA

20-11-2013

French biotech company Vect-Horus has signed a scientific collaboration agreement with Advanced Accelerator…

Advanced Accelerator ApplicationsBiotechnologyCNS DiseasesEuropeLicensingMergers & AcquisitionsVect-Horus

Rainbow Coral narrows list of regenerative medicine targets

13-11-2013

USA-based Rainbow Coral Corp says it has opened talks with its top target in the regenerative medicine…

BiotechnologyLicensingMergers & AcquisitionsRainbow Biosciences

Cytori licenses Asia-Pacific cardiovascular, renal and diabetes markets to Lorem Vascular for up to $531 million

05-11-2013

San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership…

Asia-PacificBiotechnologyCardio-vascularCytori TherapeuticsDiabetesLicensingLorem VascularMergers & AcquisitionsNephrology and Hepatology

Oxygen Biotherapeutics signs agreement to acquire Phase III cardiac drug from Phyxius Pharma

22-10-2013

US drug developer Oxygen Biotherapeutics has signed a Definitive Agreement to acquire certain assets…

Cardio-vascularLevosimendanLicensingMergers & AcquisitionsNorth AmericaOxygen BiotherapeuticsPharmaceutical

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies

07-10-2013

Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

First-half 2013 sees fall in licensing, says Evaluate

20-09-2013

Despite a positive start to the year characterized by healthy initial public offering (IPO) activity…

FinancialLicensingMergers & AcquisitionsPharmaceutical

Acetylon snags $100 million upfront cash and acquisition option

30-07-2013

Privately-held Acetylon and US biotech firm Celgene (Nasdaq: CELG) have entered into an exclusive strategic…

Acetylon PharmaceuticalsBiotechnologyCelgeneLicensingMergers & AcquisitionsNeurologicalOncology

Italy's Chiesi gains rights to uniQure's Glybera

12-07-2013

Netherlands-based venture capital backed human gene therapy firm uniQure has signed collaboration agreements…

BiotechnologyChiesi FarmaceuticiGlyberaLicensingMergers & AcquisitionsPharmaceuticaluniQure

XOMA transfers perindopril franchise rights to Symplmed

08-07-2013

California, USA-based XOMA Corp (Nasdaq: XOMA) says it has transferred US development and commercialization…

Cardio-vascularLicensingMergers & AcquisitionsperindoprilPharmaceuticalServierSymplmedXOMA Corp

MorphoSys and Celgene in deal to advance MOR202 for multiple myeloma

27-06-2013

German biotech firm MorphoSys (FSE: MOR) and USA-based Celgene (Nasdaq: CELG), the world's largest independent…

BiotechnologyCelgeneEuropeLicensingMergers & AcquisitionsMOR202MorphoSysOncology

1 to 25 of 61 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top